| Literature DB >> 30092786 |
Mingjie Zhang1, Jianxin Zhang2, Xu Sun1, Jie Xu2, Jing Zhu2, Wenbin Yuan1, Qiang Yan3.
Abstract
BACKGROUND: Previous gastrectomy can lead to an increased incidence of cholecystocholedocholithiasis (CCL) and increased morbidity rate. However, the appropriate treatment strategy for patients with CCL and a history of gastrectomy remains unclear.Entities:
Keywords: Cholecystocholedocholithiasis; Endoscopic retrograde cholangiopancreatography; Laparoscopic cholecystectomy; Laparoscopic common bile duct exploration; Previous gastrectomy
Mesh:
Year: 2018 PMID: 30092786 PMCID: PMC6085697 DOI: 10.1186/s12893-018-0388-1
Source DB: PubMed Journal: BMC Surg ISSN: 1471-2482 Impact factor: 2.102
Evaluation score table of preoperative intraabdominal adhesions
| Score (points) | ||
|---|---|---|
| Hyperplasia of original incision | No (0) | Yes (1) |
| Postoperative intestinal obstruction | No (0) | Yes (1) |
| Abdominal infection | No (0) | Yes (1) |
| Methods of gastroenterostomy | Billroth I (0) | Billroth II or Roux-en-Y (1) |
| Preoperative ultrasonography test | Lateral MD > 1 cm | Lateral MD < 1 cm |
| Longitudinal MD > 3 cm | Longitudinal MD < 3 cm | |
| (0) | (2) | |
MD Movement distance
Details of previous gastrectomy
| Billroth I ( | Gastric antrum cancer (n = 103) | Gastroduodenal ulcer ( | ||
| Stage I | 63 (61.2%) | |||
| Stage II | 40 (38.8%) | |||
| Billroth II ( | Gastric antrum cancer ( | Gastroduodenal ulcer ( | ||
| Stage I | 9 (5.7%) | Gastric ulcer | 2 (6.5%) | |
| Stage II | 62 (39.0%) | Duodenal ulcer | 29 (93.5%) | |
| Stage III | 88 (55.3%) | |||
| Roux-en-Y ( | Gastric corpus cancer ( | Gastric cardia cancer ( | ||
| Stage I | 1 (1.1%) | Stage II | 2 (16.7%) | |
| Stage II | 46 (51.7%) | Stage III | 10 (83.3%) | |
| Stage III | 42 (47.2%) | |||
Fig. 1Flow chart of performing ERCP to CCL patients with previous gastrectomy. CCL: Cholecystocholedocholithiasis; LCBDE: Laparoscopic common bile duct exploration; LC: Laparoscopic cholecystectomy; CBDE: laparotomy common bile duct exploration; ERCP: Endoscopic retrograde cholangiopancreatography; EST: Endoscopic sphincterotomy
Success rate of ERCP for CBD stones clearance in groups with different previous gastrectomy
| Previous gastrectomy | Total | Success rate of ERCP | χ2 | RR | |
|---|---|---|---|---|---|
| Billroth I | 101 | 81.2% (82/101) | 97.67 | 0.001 | 3.43a |
| Non-Billroth I | 241 | 23.7% (57/241) |
aRR = Success rate of ERCP in performing Billroth I gastrectomy group / Success rate of ERCP in performing non-Billroth I gastrectomy group
ERCP endoscopic retrograde cholangiopancreatography, CBD common bile duct, RR relative risk
Fig. 2Flow chart of performing laparoscopic surgery to CCL patients with previous gastrectomy. CCL: Cholecystocholedocholithiasis; LCBDE: Laparoscopic common bile duct exploration; LC: Laparoscopic cholecystectomy; CBDE: laparotomy common bile duct exploration; ERCP: Endoscopic retrograde cholangiopancreatography
Success rate of laparoscopic surgery in CCL patients with previous gastrectomy
| Laparoscopic surgery | Preoperative intraabdominal adhesions evaluation scores | Success rate | χ2 | RR | |
|---|---|---|---|---|---|
| LC ( | ≤ 3 points, | 96.8%(60/62) | 59.70 | 0.001 | 3.38a |
| > 3 points, | 28.6%(16/56) | ||||
| LCBDE+LC ( | ≤ 3 points, | 84.7%(50/59) | 53.41 | 0.001 | 3.27b |
| > 3 points, | 25.9%(29/112) |
aRR = Success rate of LC in evaluation scores ≤3 points group / Success rate of LC in evaluation scores > 3 points group
bRR = Success rate of LCBDE+LC in evaluation scores ≤3 points group / Success rate of LCBDE+LC in evaluation scores > 3 points group
LC Laparoscopic cholecystectomy, LCBDE Laparoscopic common bile duct exploration
Clinical outcomes of different management in CCL patients with previous gastrectomy
| Clinical outcomes | ERCP+LC, | LCBDE+LC, | |
|---|---|---|---|
| Postoperative bile leakage | 4(5.3%) | 5(6.3%) | 0.777 |
| Postoperative hemorrhage | 2(2.7%) | 4(5.1%) | 0.433 |
| Postoperative cholangitis | 10(13.2%) | 6(7.6%) | 0.255 |
| Postoperative pancreatitis | 8(10.5%) | 10(12.7%) | 0.679 |
| Residual CBD stones | 6(7.9%) | 4(5.1%) | 0.473 |
| CBD stones recurrencea | 5(6.6%) | 7(8.9%) | 0.595 |
| Bile duct stricturea | 0 | 0 | 1.0 |
| Hospital costs (RMB) | 37,652 ± 112.3 | 23,162 ± 89.6 | 0.032* |
| Hospital stay (days) | 14.7 ± 1.8 | 6.5 ± 1.5 | 0.013* |
| Death | 0 | 0 | 1.0 |
RMB (Renminbi) Currency unit of China, ERCP endoscopic retrograde cholangiopancreatography, LC Laparoscopic cholecystectomy, LCBDE Laparoscopic common bile duct exploration, CBD common bile duct
aThe median follow-up time was 37 (range 1–93) months
*p < 0.05